Octréotide : interactions médicamenteuses
Octréotide (Sandostatin, Bynfezia, Mycapssa) présente 125 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 0 de niveau majeur, 125 de niveau modéré, 0 de niveau mineur et 0 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.
Interactions d'après la notice
Interactions modérées (125)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (7.2) ]. (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (7.2) ]. (notice Octréotide, Mises en garde et précautions)
Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (7.2) ]. (notice Octréotide, Mises en garde et précautions)
Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (7.2) ]. (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (7.2) ]. (notice Octréotide, Mises en garde et précautions)
Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (7.2) ]. (notice Octréotide, Mises en garde et précautions)
Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (7.2) ]. (notice Octréotide, Mises en garde et précautions)
Bromocriptine: dose adjustment of bromocriptine may be necessary ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (7.2) ]. (notice Octréotide, Mises en garde et précautions)
Cyclosporine : may have decreased bioavailability and require dose adjustment ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (notice Octréotide, Interactions médicamenteuses)
Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Drugs Metabolized by CYP 450 Enzymes: concomitant use with other drugs mainly metabolized by CYP3A4 that have a narrow therapeutic index (e.g., quinidine) should be used with caution and increased monitoring may be required ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (notice Octréotide, Interactions médicamenteuses)
Digoxin: exposure may be decreased and assessment of clinical response to digoxin should be performed ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (7.2) ]. (notice Octréotide, Mises en garde et précautions)
Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (notice Octréotide, Interactions médicamenteuses)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (7.2) ]. (notice Octréotide, Mises en garde et précautions)
Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (notice Octréotide, Interactions médicamenteuses)
Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (notice Octréotide, Interactions médicamenteuses)
Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (notice Octréotide, Interactions médicamenteuses)
Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (notice Octréotide, Interactions médicamenteuses)
Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (notice Octréotide, Interactions médicamenteuses)
Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (notice Octréotide, Interactions médicamenteuses)
Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (notice Octréotide, Interactions médicamenteuses)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (notice Octréotide, Interactions médicamenteuses)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
- GlucagonModérée
Hyperglycemia and Hypoglycemia MYCAPSSA alters the balance between the counter-regulatory hormones, insulin, glucagon, and growth hormone, which may result in hypoglycemia, or hyperglycemia, or diabetes mellitus. (notice Octréotide, Mises en garde et précautions)
Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (7.2) ]. (notice Octréotide, Mises en garde et précautions)
Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Levonorgestrel Clinical Impact: Concomitant administration of MYCAPSSA with levonorgestrel decreases levonorgestrel bioavailability [see Clinical Pharmacology (12.3) ] . (notice Octréotide, Interactions médicamenteuses)
Levonorgestrel Clinical Impact: Concomitant administration of MYCAPSSA with levonorgestrel decreases levonorgestrel bioavailability [see Clinical Pharmacology (12.3) ] . (notice Octréotide, Interactions médicamenteuses)
Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (notice Octréotide, Mises en garde et précautions)
Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Lisinopril: bioavailability may be increased, monitor patient's blood pressure and adjust dose of lisinopril if needed ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Lisinopril: bioavailability may be increased, monitor patient's blood pressure and adjust dose of lisinopril if needed ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (notice Octréotide, Interactions médicamenteuses)
Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (notice Octréotide, Interactions médicamenteuses)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (7.2) ]. (notice Octréotide, Mises en garde et précautions)
Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (7.2) ]. (notice Octréotide, Mises en garde et précautions)
Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (notice Octréotide, Interactions médicamenteuses)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (7.2) ]. (notice Octréotide, Mises en garde et précautions)
Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (7.2) ]. (notice Octréotide, Mises en garde et précautions)
Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (notice Octréotide, Interactions médicamenteuses)
Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (notice Octréotide, Interactions médicamenteuses)
Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (notice Octréotide, Interactions médicamenteuses)
Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (notice Octréotide, Interactions médicamenteuses)
Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (notice Octréotide, Interactions médicamenteuses)
- Olmésartan, amlodipine et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée
Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (7.2) ]. (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (notice Octréotide, Interactions médicamenteuses)
Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (7.2) ]. (notice Octréotide, Mises en garde et précautions)
Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (notice Octréotide, Mises en garde et précautions)
Drugs Metabolized by CYP 450 Enzymes: concomitant use with other drugs mainly metabolized by CYP3A4 that have a narrow therapeutic index (e.g., quinidine) should be used with caution and increased monitoring may be required ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (7.2) ]. (notice Octréotide, Mises en garde et précautions)
Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary ( 7 ). (notice Octréotide, Interactions médicamenteuses)
- TélotristatModérée
Short-Acting Octreotide Concurrent administration of short-acting octreotide with Xermelo significantly decreased the systemic exposure of telotristat ethyl and telotristat, the active metabolite. (notice Télotristat, Interactions médicamenteuses)
Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (notice Octréotide, Mises en garde et précautions)
Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (notice Octréotide, Mises en garde et précautions)
Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (7.2) ]. (notice Octréotide, Mises en garde et précautions)
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). (notice Octréotide, Mises en garde et précautions)
Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary ( 7 ). (notice Octréotide, Interactions médicamenteuses)
Change in vitamin B12 levels: Monitor vitamin B 12 levels during treatment ( 5.6 ). (notice Octréotide, Mises en garde et précautions)
Vérifiez Octréotide avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.
Ouvrir dans le vérificateurCeci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.